88 Results for "

CDK12

" in MedChemExpress (MCE) Product Catalog:
Products (88)

88 Results for "CDK12" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-149819
CAS No.: 2944087-54-9
Purity:  99.60%
Target:  

HDAC CDK

Research Areas:  

Cancer

CDK/HDAC-IN-3 is an orally active HDACs/CDKs dual inhibitor. CDK/HDAC-IN-3 has potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2 and HDAC3 with IC50 values of 98.32 nM, 98.85 nM, 100 nM, 62.12 nM, 93.28nM and 82.87 nM. CDK/HDAC-IN-3 can be used for the acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-172970
CAS No.: 3093763-71-1
Research Areas:  

Cancer

HQY1428 is an orally active CDK12 inhibitor. HQY1428 inhibits DNA replication, causes G2/M arrest in SKOV3 cells, induces DNA double-strand breaks and apoptosis. HQY1428 has anti-tumor activity in the SKOV3 xenograft mouse model. HQY1428 combined with the HER2 inhibitor Lapatinib (HY-50898) in the NCI-N87 xenograft mouse model produces a synergistic therapeutic effect .
loading...
    loading...
Cat. No.: HY-176279
Research Areas:  

Cancer

Hsp90-IN-42 is a heat shock protein 90 (Hsp90) inhibitor with an IC50 of 15.65 nM against human targets. Hsp90-IN-42 destabilizes EGFR and inhibits the activation of the EGFR-Akt signaling pathway. Hsp90-IN-42 suppresses the proliferation and migration of cancer cells, induces cell cycle arrest by downregulating CDK12 and CDK13, and triggers mild apoptosis via downregulating Bcl-2 and upregulating Bax. Hsp90-IN-42 inhibits tumor growth in xenograft mouse models. Hsp90-IN-42 can be used in research related to colorectal cancer .
loading...
    loading...
Cat. No.: HY-RS02357
Research Areas:  

Others

Cdk12 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk12 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS02358
Research Areas:  

Others

Cdk12 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk12 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-177780
Research Areas:  

Cancer

Cyclin K degrader 2 is a molecular glue degrader of Cyclin K. By bridging CDK12 and DDB1, the receptor of the CRL4 E3 ligase, Cyclin K degrader 2 specifically induces the targeted degradation of Cyclin K within the CDK12-Cyclin K complex. Cyclin K degrader 2 can be used in studies related to acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-171786
CAS No.: 2928619-86-5
Target:  

CDK

Research Areas:  

Cancer

CDK12-IN-8 (Compound Cpd143) is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). CDK12-IN-8 inhibits CDK12-mediated phosphorylation of the C-terminal domain (CTD) serine 2 of RNA polymerase II, interfering with gene transcription elongation and DNA damage repair pathways. CDK12-IN-8 is promising for research of cancers with high CDK12 expression such as small cell lung cancer and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-162528
CAS No.: 3033863-94-1
Target:  

CDK

Research Areas:  

Cancer

CDK12-IN-7 (Compound 2) is a CDK12 and CDK2 inhibitor with IC50 values ​​of 42 and 196 nM, respectively. CDK12-IN-7 has anti-cell proliferation activity and can be used in cancer research .
loading...
    loading...
Cat. No.: HY-173042
CAS No.: 3076450-41-1
Target:  

CDK

Research Areas:  

Cancer

CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12/13, with IC50 values of 15.5 nM and 12.2 nM for CDK12 and CDK13, respectively. CDK12/13-IN-2 can inhibit the proliferation of breast cancer cells and can be used in the research of triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-157297
CAS No.: 3041994-96-8
Target:  

CDK

Research Areas:  

Cancer

CDK-IN-13 (compound 32E) is a potent and selective inhibitor of CDK12/cyclinK with an IC50 of 3 nM. CDK-IN-13 inhibits the growth of the HER2-positive breast cancer cell lines .
loading...
    loading...
Cat. No.: HY-139327
CAS No.: 2651196-69-7
Target:  

CDK

Research Areas:  

Cancer

CDK12-IN-4, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC50 of 0.641 μM at high ATP (2 mM). CDK12-IN-4 has no effect on CDK2/Cyclin E (IC50>20 μM) and CDK9/Cyclin T1 (IC50>20 μM) at high ATP (2 mM) (WO2021116178A1) .
loading...
    loading...
Cat. No.: HY-176790
Research Areas:  

Others

CDK12-Cyclin K ligand-1 is a ligand of PROTAC degrader that binds to the E3 ligase. CDK12-Cyclin K ligand-1 can be used in the synthesis of PROTAC degrader such as PP-C8 (HY-144691) .
loading...
    loading...
Cat. No.: HY-176791
Research Areas:  

Cancer

CDK12-Cyclin K Ligand-Linker Conjugates 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for CDK12-Cyclin K (HY-176790) and a PROTAC linker (HY-W244922), which recruits E3 ligases. CDK12-Cyclin K Ligand-Linker Conjugates 1 can be used for synthesis of PROTAC PP-C8 (HY-144691) .
loading...
    loading...
Cat. No.: HY-177743
CAS No.: 2980502-40-5
Research Areas:  

Cancer

TR-213 is a potent molecular glue degrader that targets Cyclin K (CDK). TR-213 induces 91% and 56% decrease in CDK12 and Cyclin at 1 μM. TR-213 can inhibit RNA polymerase II activity and regulates alternative polyadenylation (APA) activity. TR-213 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-150641
CAS No.: 3031561-92-6
Research Areas:  

Cancer

CDK-IN-9 (compound 24) is a potent CDK inhibitor, also as a molecular glue inducing an interaction between CDK12 and DDB1, with an IC50 values of 4 nM for CDK2/E. CDK-IN-9 leads to polyubiquitination of cyclin K and its subsequent degradation. CDK-IN-9 induce apoptosis through dephosphorylation of retinoblastoma protein and RNA polymerase II .
loading...
    loading...
Cat. No.: HY-151878
CAS No.: 3034210-97-1
Target:  

CDK GSK-3

Research Areas:  

Metabolic Disease

CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC50 value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .
loading...
    loading...
Cat. No.: HY-E70659
Target:  

CDK

Research Areas:  

Cancer

CDK12/CycK Recombinant Human Active Protein Kinase is a cyclin-dependent kinase that phosphorylates the C-terminal domain (CTD) of RNA polymerase II (Pol II), thereby regulating different phases of the transcription cycle from transcription initiation to elongation and termination .
loading...
    loading...
Cat. No.: HY-160284
CAS No.: 2407774-31-4
Target:  

CDK

Research Areas:  

Cancer

CDK12/13-IN-1 (Compound 4) is a CDK12/13 inhibitor. CDK12/13-IN-1 has antitumor activity .
loading...
    loading...
Cat. No.: HY-168658
Research Areas:  

Cancer

CDK12/13 ligand 2 is a potent CDK12 and CDK13 ligand. CDK12/13 ligand 2 can be used to synthesize YJ1206 (HY-168555) .
loading...
    loading...
Cat. No.: HY-171787
CAS No.: 2883700-83-0
Target:  

CDK

Research Areas:  

Cancer

PPA-037 is an orally active, highly potent and selective inhibitor of cyclin-dependent kinase 12 (CDK12). PPA-037 induces the degradation of cyclin K (Cyclin K), enhancing antiproliferative effects on tumor cells. PPA-037 is promising for research of cancers .
loading...
    loading...